Trends in healthcare are driven by innovation, which is largely being driven by specialty innovation, Douglas M. Long, MBA, vice president of industry relations at IMS Health, said during the headline session "Marketplace Trends" at the Academy of Managed Care Pharmacy's 27th Annual Meeting & Expo.
Trends in healthcare are driven by innovation, which is largely being driven by specialty innovation, Douglas M. Long, MBA, vice president of industry relations at IMS Health, said during the headline session “Marketplace Trends” at the Academy of Managed Care Pharmacy’s 27th Annual Meeting & Expo.
Currently, 33% of all pharmaceutical spending in the United States is specialty, compared with 23% in 2009. According to Long, experts estimate the market share will be close to 50% by 2020.
Some of the top specialty events to watch for include hepatitis C innovation with more products to come, the expensive PD-1 inhibitors in oncology, and the PCSK9 inhibitor to regulate cholesterol.
“Patient is a payer and we can’t forget that,” he said. “And one of the things, as these specialty tiers copayments go up, is a lot of times they say ‘I’m not taking the drug.’”
Generics and Biosimilars
Although half of the generic prices have gone down and half have gone up, 20% of those that went up in price “went up big time,” Long said.
There are a few reasons why the price of generics is going up. First, the bar on regulatory and quality has been raised; second, there is customer consolidation; and third, there have been fewer product launches.
Another opportunity is with biologics as patents begin to expire between now and the end of the decade.
“We finally have a biosimilar marketplace that looks like it’s ready to start in the US,” he said.
The biosimilar market should not be confused with a generic market, Long said. The cost to bring a biosimilar to market is $200 million on average and no company will give a 90% discount on development costs that high.
“If they did, they’re just slitting their own throat,” he said.
Cost Containment Strategies
There is now greater collaboration in healthcare than there has ever been before, particularly when it comes to preventing hospital readmissions for Medicare patients.
Running through the evolution of managed care, he pointed out that there has been increasing integration over time. The industry started with fee-for-service pre-1980s before moving to health maintenance organizations in the 1980s and 1990s and the early integrated delivery networks (IDNs) in the first decade of the 21st century. Now is the time of advanced IDNs, and by 2020 he expects the industry will have moved to population management.
“The lines are starting to blur,” Long said. “Two-thirds of health networks are part of [accountable care organizations] now. You have the blurring between delivery and health insurance through vertical integration.”
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More